In a number of clinical trials, patients with type 2 diabetes exhibited comparable HbA1c reductions (24–27) and rates of achieving target HbA1c goals (≤ 7.0%) (24,27) when administered insulin glargine or NPH insulin. This evidence concerns the gene INS and type 2 diabetes mellitus.